(i) EA/17.70 ± 9.93m (ii) Progynova + medroxyprogesterone acetate/18.27 ± 8.61 m
CCMD-2
NR
(i) 30 min/day, 3 days/week for 12 weeks (ii) sparse-dense wave, 2/15 Hz
CV4; EX-CA1; EX-HN3; HT7; SP6; ST25
(i) A total of 3 treatment cycles. Each treatment cycle includes Progynova 1 mg daily for 21 consecutive days (with medroxyprogesterone acetate 10 mg daily added from day 14 to day 21) and then stop medication for 7 days
(i) PSQI (ii) KI (iii) MENQOL (iv) FSH (v) E2
(i) Compared with Progynova + medroxyprogesterone acetate < 0.05 (ii) Compared with Progynova + medroxyprogesterone acetate > 0.05 (iii) Compared with Progynova + medroxyprogesterone acetate > 0.05 (iv) Compared with Progynova + medroxyprogesterone acetate > 0.05 (v) Compared with Progynova + medroxyprogesterone acetate < 0.05
(i) Available data for 3 months follow-up
(i) EA/n = 3 (two for hematoma; one for mild dizziness) (ii) Progynova + medroxyprogesterone acetate/n = 4 (two for breast tenderness; one for mild headache; one for colporrhagia)
(i) EA/n = 41 (ii) Estazolam/n = 41 (iii) Herbal medicine/n = 41 (iv) EA + Herbal medicine/n = 42
(i) EA/50.17 ± 2.46 (ii) Estazolam/50.45 ± 3.19 (iii) Herbal medicine/49.76 ± 3.05 (iv) EA + Herbal medicine/50.61 ± 2.62
(i) EA/2.33 ± 0.72 y (ii) Estazolam/2.06 ± 0.85 y (iii) Herbal medicine/1.93 ± 1.05 y (iv) EA + Herbal medicine/1.96 ± 0.99 y
CCMD-3
NR
(i) 30 min/day, 6 days/week for 4 weeks (ii) Continuous wave, >50 Hz
PC6, SP6, Sishenzhen (1.5 Cun apart from GV20), Dingshenzhen (0.5 Cun up to EX-HN3, and 0.5 Cun up to GB14)
(i) Estazolam 1 mg/day, 7 days/week for 4 weeks
(i) PSQI (ii) KI (iii) WHOQOL-BREF (iv) FSH (v) E2
(i) Compared with Estazolam < 0.05 (ii) Compared with Estazolam < 0.05 (iii) Compared with Estazolam < 0.05 (iv) Compared with Estazolam < 0.05 (v) Compared with Estazolam < 0.05
(i) EA/13.36 ± 7.47 m (ii) Estazolam/13.51 ± 7.76 m
CCMD-2
(i) Excessive Liver fire due to emotional suppression (ii) Disturbance of heart due to phlegm heat (iii) Yin deficiency leading to excessive fire (iv) Heart and spleen deficiency (v) Heart and gallbladder Qi deficiency
(i) 30 min/day, 3 days/week for 4 weeks (ii) Continuous wave, >50 Hz
PC6, SP6, Sishenzhen (1.5 Cun apart from GV20), Dingshenzhen (0.5 Cun up to EX-HN3, and 0.5 Cun up to GB14)
(i) Estazolam 1 mg/day, 7 days/week for 4 weeks
(i) PSQI (ii) HAMD
(i) Compared with Estazolam < 0.01 (ii) Compared with Estazolam < 0.01
(i) MA/18.44 ± 7.55 m (ii) Estazolam/20.58 ± 9.25 m
CCMD-3, ICD-10, CDTE-TCM
(i) Deficiency of kidney and hyperactivity of liver
(i) 30 min/day, 5 days/week for 4 weeks
BL17, BL18, BL23, EX, EX-HN1, GV20, KI3, LR3
(i) Estazolam 1–2 mg/day, 7 days/week for 4 weeks
(i) PSQI (ii) HAMA (iii) light-sleep (%) (iv) deep-sleep (%) (v) REM (%) (iii)-(v) are recorded by MSMSMS
(i) Compared with Alprazolam > 0.05 (ii) Compared with Estazolam < 0.05 (iii) Compared with Estazolam < 0.05 (iv) Compared with Estazolam < 0.05 (v) Compared with Estazolam < 0.05
No follow-up
(i) MA/n = 3 (hematoma) (ii) Estazolam/n = 7 (two for dizziness; two for daytime sleepiness; three for fatigue)
(i) 30 min/day, 15 days/month (one treatment every other day) for 3 months
CV12, HT7, KI3, PC6, ST36, ST40, four scalp acupoints (middle 1/3 of frontal apical band, posterior 1/3 of frontal apical band, anterior 1/3 of skull base band, middle 1/3 of skull base band)
(i) Estazolam 1 mg/day, 10 days/month for 3 months
(i) PSQI (ii) FSH (iii) E2 (iv) LH
(i) Compared with Estazolam < 0.05 (ii) Compared with Estazolam < 0.05 (iii) Compared with Estazolam < 0.05 (iv) Compared with Estazolam < 0.05